Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Melanoma 72Carcinoma, Renal Cell 26Kidney Neoplasms 22Skin Neoplasms 16Neoplasm Metastasis 14Leukemia, Myeloid, Acute 13Leukemia 13Breast Neoplasms 11Lymphoma 10Lymphoma, Non-Hodgkin 9Ovarian Neoplasms 8Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Pancreatic Neoplasms 5Neuroblastoma 5Myelodysplastic Syndromes 5Multiple Myeloma 5Lymphoma, Mantle-Cell 5Lung Neoplasms 5Congenital Abnormalities 5Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, Large B-Cell, Diffuse 4Liver Neoplasms 4Hodgkin Disease 4Gliosarcoma 4Glioblastoma 4Colorectal Neoplasms 4Central Nervous System Neoplasms 4Uterine Cervical Neoplasms 3

Interventions

pembrolizumab 6Cisplatin 5Radiotherapy 4Paclitaxel 3Nivolumab 3lenvatinib 2Specimen Handling 2Platinum 2Papillomavirus Vaccines 2Magnetic Resonance Spectroscopy 2Ipilimumab 2Gemcitabine 2Carboplatin 2CTLA-4 Antigen 2Bleomycin 2Bevacizumab 21,2-diaminocyclohexaneplatinum II citrate 2zimberelimab 1rocakinogene sifuplasmid 1liposomal doxorubicin 1durvalumab 1dostarlimab 1cemiplimab 1belzutifan 1antineoplaston AS 2-1 1antineoplaston A10 1alovudine 1aldesleukin 1Watchful Waiting 1Vorinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Vulvar Neoplasms × aldesleukin × Clear all
NCT05686226 2026-02-27

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

Rutgers, The State University of New Jersey

Phase 2 Recruiting
20 enrolled
GastrointestinalGenitourinaryGynecologicHead & Neck

Anus Neoplasms, Uterine Cervical Neoplasms, Neoplasm Metastasis, Oropharyngeal Neoplasms, Penile Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡